In 2024, the Genotyping Market in Latin America had consolidated and has grown significantly. Three main drivers primarily led to this growth: technological adoption, investments, and prevailing health conditions in the region. Latin American countries, especially Brazil and Mexico, have shown increased adoption of advanced genotyping technologies, such as next-generation sequencing, impacting the market positively. With investments and government funding on the rise in the healthcare sector, these countries have been able to attain progressive genotyping research and product launches. Additionally, high prevalence of diseases, like cancer in Argentina, and infectious diseases in Colombia, boosted the need for genotyping to develop specialized treatments.
The market witnessed few major trends throughout 2024. Firstly, a surge in collaborations and partnerships among key industry players and research institutes, like in Chile, to exploit genotyping's potential in disease diagnostics and personalized medicine. Secondly, policy changes in some countries, like Peru, fostered market growth by implementing regulations supporting progress in molecular diagnostics. Finally, there was a shift in the buyer's behavior towards understanding the benefits of predictive and personalized healthcare. The primary customer sectors included healthcare, pharmaceuticals, academic research institutes, and biotechnological entities. The market growth also got impacted by changing channel dynamics, with online platforms having a vital role in the genotyping product distribution.
